Following the introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of
chronic myeloid leukemia (CML) patients, the allogeneic hematopoietic stem cell …

BCR-ABL1 fusion transcript is the minimal residual disease marker in chronic myeloid
leukemia; 2% of patients show unusual breakpoints generating atypical transcripts, not …

The monitoring of minimal residual disease (MRD) through low sensitivity real-time (RT)
polymerase chain reaction (PCR) analysis of BCR-ABL transcripts allows early detection of …

Previous studies concerning BCR‐ABL mRNA levels by quantitative real‐time RT‐PCR (Q‐
PCR) for chronic myelogenous leukemia (CML) have shown a significant concordance …

BCR‐ABL1‐positive leukemias have historically been classified as either chronic
myelogenous leukemia or Ph+ acute lymphoblastic leukemia. Recent analyses suggest …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by the
expansion of a leukemic stem cell (LSC) clone, carring a Philadelphia translocation, able to …

Most chronic myeloid leukemia (CML) patients show the Philadelphia chromosome (Ph)
arising from the reciprocal t (9; 22), but 5–10% present variants of this translocation involving …

Introducción: la leucemia mieloide crónica (LMC) es un síndrome mieloproliferativo crónico
caracterizado por la presencia de una alteración citogenética en las células proliferantes, el …

Background Multiple organizations produce guidance documents that provide opportunities
to harmonize quality practices for diagnostic testing. The International Organization for …

The current treatment of chronic myelogenous leukemia (CML) is one of the most successful
examples of molecularly targeted therapy in cancer. The identification of the fusion …